Completed NA INTERVENTIONAL 1-arm NCT02814630

Three-month, Single-center Study to Identify Biomarkers/Response to Xolair Therapy in Chronic Idiopathic Urticaria

Three-month, Single-center Study to Identify Biomarkers (Plasma Exosomal miRNAs) and Mechanism of Response (Basophil Transcriptome Analysis) to Xolair® (Omalizumab) in Patients With Chronic Idiopathic Urticaria

Sponsor: Asthma Inc Clinical Research Center

Conditions Chronic Idiopathic Urticaria

Interventions Xolair

Updated 7 times since 2017 Last updated: Jan 22, 2019 Started: Sep 30, 2016 Primary completion: Nov 2, 2018 Completion: Nov 2, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This NA trial investigates Chronic Idiopathic Urticaria and is currently completed. Asthma Inc Clinical Research Center leads this study, which shows 7 recorded versions since 2016 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA
Feb 2019 — Jan 2021 [monthly]

Completed NA

Status: Recruiting → Completed
Jun 2018 — Feb 2019 [monthly]

Recruiting NA

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Recruiting NA
Jan 2017 — Feb 2017 [monthly]

Recruiting NA

First recorded

Sep 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Asthma Inc Clinical Research Center
University of Washington

Data source: Asthma Inc Clinical Research Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seattle, United States